Increasing Collaboration Between Big Pharma and Academia to Counter R&D, Patent and Approval Issues in the Industry

Date: August 1, 2011
Pages: 7
Price:
US$ 500.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: I25B98AFF32EN
Leaflet:

Download PDF Leaflet

Increasing Collaboration Between Big Pharma and Academia to Counter R&D, Patent and Approval Issues in the Industry
Increasing Collaboration Between Big Pharma and Academia to Counter R&D, Patent and Approval Issues in the Industry

Summary

GlobalData’s viewpoint, “Increasing Collaboration Between Big Pharma and Academia to Counter R&D, Patent and Approval Issues in the Industry” is a featured article highlighting the importance of increasing collaboration between Big Pharma and Academia to Counter R&D and how it is developing as a new business model has become an important issue

Scope
  • This report will describe the strategic overview, history of deals, major resent failures nature of the collaboration agreements and reasons for the increasing trend towards collaboration of big pharma and academia
Reasons to buy
  • Understand the limitations of these kind of collaborations with risk and benefits analysis.
  • This report will enable companies to decide their strategy for pipeline development
1 TABLE OF CONTENTS2 SUMMARY3 INCREASING COLLABORATION BETWEEN BIG PHARMA AND ACADEMIA TO COUNTER R&D, PATENT AND APPROVAL ISSUES IN THE INDUSTRY

3.1 Overview of Collaborations
  3.1.1 Strategy Overview
  3.1.2 Deals History
  3.1.3 Recent High Profile Failures in the Late-Stage Pipeline
3.2 The Nature of the Collaboration Agreements
3.3 Reasons for the Increasing Trend Towards Collaboration
  3.3.1 The Increasing Number of Drug Failures in Late-stage Pipeline Requires New Ways of Working
  3.3.2 Enhancing Early-stage Drug Discovery will Increase Innovation
  3.3.3 Pharmaceutical Companies’ R&D Budgets are being Reduced as Costs Spiral
  3.3.4 Academic Institutions can Compensate for Budget Cuts
  3.3.5 Problems in Ways of Working are being Overcome
3.4 Impact of Collaboration
  3.4.1 Biotechnology Companies are Following Big Pharma and Making Deals with Academia
  3.4.2 Results Will Take Time to Become Apparent but Increase in Number of Approved and Novel Molecules Expected
  3.4.3 Future Agreements Between Academia and Industry Will be More Common and Easier to Implement
3.5 Future Trend

4 APPENDIX

4.1 Research Methodology
4.2 Secondary Research
4.3 Primary Research
4.4 Models
4.5 Forecasts
4.6 Expert Panels
4.7 GlobalData Consulting
4.8 Contact Us
4.9 Disclaimer

Ask Your Question

Increasing Collaboration Between Big Pharma and Academia to Counter R&D, Patent and Approval Issues in the Industry
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: